FIELD: medicine, dermatovenerology. SUBSTANCE: preparation showing local vasoconstriction effect, for example, 0.015-0.05% halazolin or naphthyzin and (2.5-5.0) x 2,5 - 5,0 × 105 МЕ/мл IU/ml genetic-engineering α2-interferon and (2.5-5.0) x 2,5 - 5,0 × 104 МЕ/мл IU/ml genetic-engineering γ-interferon 2-5 times per 24 h for 2 days are applied on the damaged skin regions and/or mucous membranes beginning of the first day of disease. Interferons in combination with vasoconstriction preparation are administrated into nose cavity at viral rhinitis (1-3 drops per one life year of patient but not more than 20 drops) into the every nostril. Solution of vasoconstriction preparation in combination with genetic-engineering interferons is applied also on the damage foci in the form of lotions in the case of skin and/or mucous membrane diseases caused by simplex virus. Method can be used for prophylaxis and treatment of viral rhinitis, skin and/or mucous membrane diseases caused by simplex virus. EFFECT: increased effectiveness of method. 3 cl
Title | Year | Author | Number |
---|---|---|---|
METHOD OF INFECTIOUS SKIN DISEASE TREATMENT | 1992 |
|
RU2021814C1 |
METHOD OF TREATMENT WITH CYTOKINE PREPARATIONS | 1992 |
|
RU2063036C1 |
METHOD OF MEDICAL THERAPEUTIC TREATMENT OF RHINITIS, FORMED IN PATIENTS RECEIVING NASAL DECONGESTANTS | 2017 |
|
RU2684563C2 |
BIOLOGICALLY ACTIVE ADDITIVE | 1998 |
|
RU2129394C1 |
METHOD OF PREPARING PERORAL MEDICINAL FORM OF CYTOKINE (ITS VARIANTS) | 1993 |
|
RU2060729C1 |
AGENT ELICITING IMMUNOMODULATING, ANTIVIRAL, ANTIBACTERIAL, REGENERATING, REPARATIVE, MEMBRANE-AND HEPATOPROTECTIVE EFFECT | 2002 |
|
RU2216345C1 |
ANTIVIRAL, ANTIBACTERIAL AND ANTICANDIDOSIS AGENT | 1999 |
|
RU2144832C1 |
METHOD OF TREATING PATIENTS WITH INFECTIOUS DISEASES | 1999 |
|
RU2146531C1 |
METHOD OF ADMINISTRATION OF PREPARATION CONTAINING RECOMBINANT α-INTERFERON | 1999 |
|
RU2174406C2 |
MEDICINAL GEL | 2000 |
|
RU2184564C2 |
Authors
Dates
1994-11-15—Published
1992-05-06—Filed